Fidson, Chinese Firms to Build Pharmaceutical Plant in Lagos
Fidson Healthcare Plc has signed a Strategic Cooperation Memorandum with Jiangsu Aidea Pharma, Nanjing PharmaBlock, and the China-Africa Development Fund in Beijing, China, to build a pharma plan in Nigeria.
In an official statement, the healthcare company said the signing ceremony took place during a visit by a team from Nigeria led by Dr. Fidelis Ayebae, the founder and Managing Director of Fidson Healthcare Plc.
Fidson said the 4 (four) parties have agreed to actively leverage their respective strengths to establish a new joint venture pharmaceutical plant project in Nigeria. This new project is poised to promote Africa’s self-reliance in healthcare delivery, especially in tackling HIV, the Pharmaceutical company added.
“All parties agreed to share information and resources, jointly explore investment opportunities in the pharmaceutical markets of West African countries and implement investment cooperation at the project level”.
This signing ceremony follows a series of engagements, including a visit by the Chairman of Jiangsu Aidea Pharma- Dr. Heliang Fu to Nigeria earlier in the year.
During the visit, Dr. Fu toured the Lekki Free Trade Zone, which is the chosen site for the state-of-the-art manufacturing facility that is set to revolutionize the pharmaceutical industry in Nigeria and the wider African continent.
The partnership between Fidson and the Chinese firms is a sterling example of international cooperation aimed at tackling pressing medical challenges.
The upcoming manufacturing facility will become a hub for pharmaceutical excellence, leveraging the Lekki Free Trade Zone’s strategic location and comprehensive infrastructure to foster economic growth and healthcare improvement.
In the words of Dr. Fu, “This collaboration marks an important step for Chinese Pharma players in their commitment to global medical cooperation.
“By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients.”
On his part, Dr. Ayebae expressed optimism about the partnership saying that “We eagerly look forward to this collaboration and believe that the complementary strengths of all parties will inject new vitality into the Healthcare delivery sector in Africa, particularly addressing the medical needs of over 1.9 million HIV-infected individuals in Nigeria, a focus of Aidea Pharma.”
He added that the project is coming at no better time as the National Agency for the Control of AIDS (NACA) in Nigeria, under the leadership of Dr. Temitope Ilori is championing the government’s drive to provide necessary support and the enabling environment for pharmaceutical companies to start local production of Anti-Retroviral drugs (ARVs).
#Fidson, 3 Chinese Firms to Build Pharmaceutical Plant in Lagos Ecobank Advises Businesses to take advantage of its Single Market Trade Hub
